Cargando…
Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor ef...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769585/ https://www.ncbi.nlm.nih.gov/pubmed/24039617 http://dx.doi.org/10.1007/s11306-013-0517-x |
_version_ | 1782284001400061952 |
---|---|
author | Cao, Bei Li, Mengjie Zha, Weibin Zhao, Qijin Gu, Rongrong Liu, Linsheng Shi, Jian Zhou, Jun Zhou, Fang Wu, Xiaolan Wu, Zimei Wang, Guangji Aa, Jiye |
author_facet | Cao, Bei Li, Mengjie Zha, Weibin Zhao, Qijin Gu, Rongrong Liu, Linsheng Shi, Jian Zhou, Jun Zhou, Fang Wu, Xiaolan Wu, Zimei Wang, Guangji Aa, Jiye |
author_sort | Cao, Bei |
collection | PubMed |
description | Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor effect and resistance of adriamycin, the drug-sensitive MCF-7S and the drug-resistant MCF-7Adr breast cancer cells were used and treated with adriamycin, and the intracellular metabolites were profiled using gas chromatography mass spectrometry. Principal components analysis of the data revealed that the two cell lines showed distinctly different metabolic responses to adriamycin. Adriamycin exposure significantly altered metabolic pattern of MCF-7S cells, which gradually became similar to the pattern of MCF-7Adr, indicating that metabolic shifts were involved in adriamycin resistance. Many intracellular metabolites involved in various metabolic pathways were significantly modulated by adriamycin treatment in the drug-sensitive MCF-7S cells, but were much less affected in the drug-resistant MCF-7Adr cells. Adriamycin treatment markedly depressed the biosynthesis of proteins, purines, pyrimidines and glutathione, and glycolysis, while it enhanced glycerol metabolism of MCF-7S cells. The elevated glycerol metabolism and down-regulated glutathione biosynthesis suggested an increased reactive oxygen species (ROS) generation and a weakened ability to balance ROS, respectively. Further studies revealed that adriamycin increased ROS and up-regulated P-gp in MCF-7S cells, which could be reversed by N-acetylcysteine treatment. It is suggested that adriamycin resistance is involved in slowed metabolism and aggravated oxidative stress. Assessment of cellular metabolomics and metabolic markers may be used to evaluate anti-tumor effects and to screen for candidate anti-tumor agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-013-0517-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3769585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-37695852013-09-13 Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells Cao, Bei Li, Mengjie Zha, Weibin Zhao, Qijin Gu, Rongrong Liu, Linsheng Shi, Jian Zhou, Jun Zhou, Fang Wu, Xiaolan Wu, Zimei Wang, Guangji Aa, Jiye Metabolomics Original Article Continuous exposure of breast cancer cells to adriamycin induces high expression of P-gp and multiple drug resistance. However, the biochemical process and the underlying mechanisms for the gradually induced resistance are not clear. To explore the underlying mechanism and evaluate the anti-tumor effect and resistance of adriamycin, the drug-sensitive MCF-7S and the drug-resistant MCF-7Adr breast cancer cells were used and treated with adriamycin, and the intracellular metabolites were profiled using gas chromatography mass spectrometry. Principal components analysis of the data revealed that the two cell lines showed distinctly different metabolic responses to adriamycin. Adriamycin exposure significantly altered metabolic pattern of MCF-7S cells, which gradually became similar to the pattern of MCF-7Adr, indicating that metabolic shifts were involved in adriamycin resistance. Many intracellular metabolites involved in various metabolic pathways were significantly modulated by adriamycin treatment in the drug-sensitive MCF-7S cells, but were much less affected in the drug-resistant MCF-7Adr cells. Adriamycin treatment markedly depressed the biosynthesis of proteins, purines, pyrimidines and glutathione, and glycolysis, while it enhanced glycerol metabolism of MCF-7S cells. The elevated glycerol metabolism and down-regulated glutathione biosynthesis suggested an increased reactive oxygen species (ROS) generation and a weakened ability to balance ROS, respectively. Further studies revealed that adriamycin increased ROS and up-regulated P-gp in MCF-7S cells, which could be reversed by N-acetylcysteine treatment. It is suggested that adriamycin resistance is involved in slowed metabolism and aggravated oxidative stress. Assessment of cellular metabolomics and metabolic markers may be used to evaluate anti-tumor effects and to screen for candidate anti-tumor agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-013-0517-x) contains supplementary material, which is available to authorized users. Springer US 2013-03-20 2013 /pmc/articles/PMC3769585/ /pubmed/24039617 http://dx.doi.org/10.1007/s11306-013-0517-x Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Cao, Bei Li, Mengjie Zha, Weibin Zhao, Qijin Gu, Rongrong Liu, Linsheng Shi, Jian Zhou, Jun Zhou, Fang Wu, Xiaolan Wu, Zimei Wang, Guangji Aa, Jiye Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title | Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title_full | Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title_fullStr | Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title_full_unstemmed | Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title_short | Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
title_sort | metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769585/ https://www.ncbi.nlm.nih.gov/pubmed/24039617 http://dx.doi.org/10.1007/s11306-013-0517-x |
work_keys_str_mv | AT caobei metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT limengjie metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT zhaweibin metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT zhaoqijin metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT gurongrong metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT liulinsheng metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT shijian metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT zhoujun metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT zhoufang metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT wuxiaolan metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT wuzimei metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT wangguangji metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells AT aajiye metabolomicapproachtoevaluatingadriamycinpharmacodynamicsandresistanceinbreastcancercells |